PL2424520T3 - Zastosowanie PUFA do leczenia stanów zapalnych skóry - Google Patents

Zastosowanie PUFA do leczenia stanów zapalnych skóry

Info

Publication number
PL2424520T3
PL2424520T3 PL10717730T PL10717730T PL2424520T3 PL 2424520 T3 PL2424520 T3 PL 2424520T3 PL 10717730 T PL10717730 T PL 10717730T PL 10717730 T PL10717730 T PL 10717730T PL 2424520 T3 PL2424520 T3 PL 2424520T3
Authority
PL
Poland
Prior art keywords
pufas
treating skin
skin inflammation
inflammation
treating
Prior art date
Application number
PL10717730T
Other languages
English (en)
Inventor
Adam Kelliher
Angus Morrison
Phil Knowles
Original Assignee
Ds Biopharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ds Biopharma Limited filed Critical Ds Biopharma Limited
Publication of PL2424520T3 publication Critical patent/PL2424520T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL10717730T 2009-04-29 2010-04-29 Zastosowanie PUFA do leczenia stanów zapalnych skóry PL2424520T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0907413.9A GB0907413D0 (en) 2009-04-29 2009-04-29 Novel methods
US17781109P 2009-05-13 2009-05-13
PCT/GB2010/000844 WO2010125340A1 (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
EP10717730.5A EP2424520B1 (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation

Publications (1)

Publication Number Publication Date
PL2424520T3 true PL2424520T3 (pl) 2020-02-28

Family

ID=40792027

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10717730T PL2424520T3 (pl) 2009-04-29 2010-04-29 Zastosowanie PUFA do leczenia stanów zapalnych skóry

Country Status (21)

Country Link
US (8) US8536223B2 (pl)
EP (2) EP3607945A1 (pl)
JP (9) JP5794978B2 (pl)
KR (1) KR101365801B1 (pl)
CN (2) CN103816144A (pl)
AU (1) AU2010243378B2 (pl)
CA (2) CA2760629C (pl)
CY (1) CY1122139T1 (pl)
DK (1) DK2424520T3 (pl)
ES (1) ES2745458T3 (pl)
GB (1) GB0907413D0 (pl)
HR (1) HRP20191817T1 (pl)
HU (1) HUE046581T2 (pl)
LT (1) LT2424520T (pl)
NZ (1) NZ596191A (pl)
PL (1) PL2424520T3 (pl)
PT (1) PT2424520T (pl)
SG (1) SG175823A1 (pl)
SI (1) SI2424520T1 (pl)
SM (1) SMT201900619T1 (pl)
WO (1) WO2010125340A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP2708230B1 (en) 2011-05-12 2024-10-02 Nissui Corporation Composition for external skin use for inflammatory diseases
US9855236B2 (en) * 2011-10-19 2018-01-02 Ds Biopharma Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201401629XA (en) * 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
WO2014022816A2 (en) * 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
CN114410374B (zh) 2013-12-04 2025-01-07 株式会社日水 微生物油、微生物油的制造方法、浓缩微生物油及浓缩微生物油的制造方法
US20170000752A1 (en) * 2014-01-24 2017-01-05 Kyoto University Anti-inflammatory agent containing rare fatty acid
RU2714323C2 (ru) 2014-06-04 2020-02-14 ДиЭс БАЙОФАРМА ЛИМИТЕД Фармацевтические композиции, содержащие дглк, и их применение
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3861995A1 (en) 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
CN110302193B (zh) * 2019-08-14 2022-02-18 中南大学湘雅三医院 一种纳米酸化脂肪酸酯复合物在制备治疗面部毛囊虫皮炎药物中的应用
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
KR102867098B1 (ko) * 2024-12-02 2025-10-02 한국콜마주식회사 아마씨오일 유래 지방산 유도체

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5264452A (en) 1975-11-18 1977-05-27 Nippon Suisan Kaisha Ltd Method of producing processed fish meat
JPS5820575B2 (ja) 1975-11-27 1983-04-23 日本水産株式会社 スイサンカコウヒンノセイゾウホウ
US4444755A (en) 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
EP0004770B1 (en) 1978-04-11 1984-06-13 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
IE51145B1 (en) 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
IE53332B1 (en) 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
US4386072A (en) 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
US5324748A (en) 1981-07-14 1994-06-28 Efamol Limited Method for enhancement of 1-series PG production
AU556817B2 (en) 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
US5145686A (en) 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
EP0087865B1 (en) 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
ATE19855T1 (de) 1982-03-01 1986-06-15 Efamol Ltd Pharmazeutische und diaetetische zusammensetzung.
EP0087864B1 (en) 1982-03-01 1986-10-15 Efamol Limited Pharmaceutical composition
ATE22533T1 (de) 1982-04-29 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8326130D0 (en) 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
GB8420771D0 (en) 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
GB8425006D0 (en) 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
CH663951A5 (fr) 1984-10-10 1988-01-29 Nestle Sa Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant.
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB8522670D0 (en) 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
CH669208A5 (fr) 1986-12-17 1989-02-28 Nestle Sa Procede de fractionnement en continu d'un melange d'acides gras.
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
EP0309086A1 (en) 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
DE68924714T2 (de) 1988-01-14 1996-05-02 Anders Frithz Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
GB8806737D0 (en) 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
US6140304A (en) 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB8920228D0 (en) 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
JPH04290820A (ja) * 1991-03-18 1992-10-15 Idemitsu Petrochem Co Ltd 皮膚病犬の治療方法とその薬剤
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
GB9112052D0 (en) 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
JP3354581B2 (ja) 1991-09-30 2002-12-09 サントリー株式会社 ジホモ−γ−リノレン酸及びこれを含有する脂質の製造方法
GB9211229D0 (en) * 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
DE4238869C2 (de) 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US5709855A (en) * 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
GB9621373D0 (en) 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2002515480A (ja) 1998-05-15 2002-05-28 ユニバーシティ オブ バーモント １６−ヒドロキシエイコサテトラエン酸の新規アナログ
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
HK1045302B (en) 1999-11-09 2005-10-14 Alcon, Inc. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
CA2304906A1 (en) 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
JP2002047176A (ja) 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd ＩｇＥ産生抑制剤
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US20020198177A1 (en) 2001-05-30 2002-12-26 Horrobin David Frederick Coenzyme Q and EPA
US20030073930A1 (en) 2001-10-17 2003-04-17 Morrissey Gerald R. Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females
US20030105445A1 (en) 2001-11-30 2003-06-05 Kimberly-Clark Worldwide, Inc. Breast pad assembly containing a skin benefit ingredient
US20030194446A1 (en) 2002-04-10 2003-10-16 Akes Lindy K. Zinc oxide compositions for dermatheraputics
WO2004026259A2 (en) 2002-09-20 2004-04-01 Griscom Bettle, Iii Transdermal compositions
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
ES2529572T3 (es) 2004-04-22 2015-02-23 Commonwealth Scientific And Industrial Research Organisation Síntesis de ácidos grasos poliinsaturados de cadena larga por células recombinantes
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
CA2572344A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
WO2006085687A1 (ja) * 2005-02-14 2006-08-17 Suntory Limited ジホモ−γ−リノレン酸（ＤＧＬＡ）を有効成分として含んで成る組成物
JP5546087B2 (ja) * 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
JP2006306812A (ja) 2005-04-28 2006-11-09 Suntory Ltd 好酸球浸潤抑制剤
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CN101426914A (zh) 2005-12-30 2009-05-06 因特拉迪格姆公司 促进皮肤的无疤痕伤口痊愈的siRNA组合物以及用于伤口治疗的方法
US9150817B2 (en) 2006-04-13 2015-10-06 Nippon Suisan Kaisha, Ltd. Process for preparing concentrated polyunsaturated fatty acid oil
GB0611240D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2008021192A2 (en) 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
FR2906716B1 (fr) 2006-10-06 2013-05-17 Clarins Lab Utilisation d'une composition cosmetique pour le soin des peaux grasses.
US20080125487A1 (en) 2006-11-17 2008-05-29 Tapas Das Elongase gene and uses thereof
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
US20080213357A1 (en) 2007-02-12 2008-09-04 Andrew Bruce Hebard Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications
ITMI20070555A1 (it) 2007-03-21 2007-06-20 Giuliani Spa Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US8455035B2 (en) 2008-04-25 2013-06-04 Basf Plant Science Gmbh Plant seed oil
EP2159732A1 (en) 2008-08-21 2010-03-03 Thomson Licensing Method and device for code obfuscation
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
GB0907601D0 (en) 2009-05-01 2009-06-10 Equateq Ltd Novel methods
US8524485B2 (en) 2009-06-16 2013-09-03 E I Du Pont De Nemours And Company Long chain omega-3 and omega-6 polyunsaturated fatty acid biosynthesis by expression of acyl-CoA lysophospholipid acyltransferases
US8188335B2 (en) 2009-07-17 2012-05-29 Abbott Laboratories Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
WO2012087745A1 (en) 2010-12-21 2012-06-28 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
EP2508180A1 (en) 2011-04-04 2012-10-10 Nestec S.A. Sn-1(3) Monoacylglycerides and lipid absorption
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
CN104321055A (zh) 2012-01-06 2015-01-28 翁特拉制药公司 游离酸形式的ω-3多不饱和脂肪酸的富含dpa组合物
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
US20150079164A1 (en) 2012-04-04 2015-03-19 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
EP4205546A1 (en) 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
US8729726B2 (en) * 2012-10-12 2014-05-20 M. Hassan Hassan Petroleum-alternative power plant
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
RU2714323C2 (ru) 2014-06-04 2020-02-14 ДиЭс БАЙОФАРМА ЛИМИТЕД Фармацевтические композиции, содержащие дглк, и их применение
WO2017118911A1 (en) 2016-01-07 2017-07-13 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Also Published As

Publication number Publication date
AU2010243378B2 (en) 2014-03-27
JP6254138B2 (ja) 2017-12-27
CY1122139T1 (el) 2020-11-25
CA2843996A1 (en) 2010-11-04
EP2424520B1 (en) 2019-07-24
CA2843996C (en) 2022-07-12
JP2016029115A (ja) 2016-03-03
US20120142773A1 (en) 2012-06-07
JP5794978B2 (ja) 2015-10-14
JP2020143138A (ja) 2020-09-10
SG175823A1 (en) 2011-12-29
LT2424520T (lt) 2019-10-25
JP2017061495A (ja) 2017-03-30
JP6951506B2 (ja) 2021-10-20
HK1165728A1 (en) 2012-10-12
CA2760629A1 (en) 2010-11-04
US20120213824A1 (en) 2012-08-23
US9421163B2 (en) 2016-08-23
KR20120013394A (ko) 2012-02-14
EP3607945A1 (en) 2020-02-12
US20180116991A1 (en) 2018-05-03
KR101365801B1 (ko) 2014-02-20
US8729126B2 (en) 2014-05-20
US9889106B2 (en) 2018-02-13
EP2424520A1 (en) 2012-03-07
CN103816144A (zh) 2014-05-28
JP6785027B2 (ja) 2020-11-18
HRP20191817T1 (hr) 2019-12-27
CN102458391B (zh) 2014-06-04
SI2424520T1 (sl) 2019-11-29
US10918614B2 (en) 2021-02-16
JP2018145195A (ja) 2018-09-20
GB0907413D0 (en) 2009-06-10
AU2010243378A1 (en) 2011-11-24
US20140194399A1 (en) 2014-07-10
US20140309304A1 (en) 2014-10-16
US20160324819A1 (en) 2016-11-10
JP2018150361A (ja) 2018-09-27
US9216151B2 (en) 2015-12-22
NZ596191A (en) 2014-07-25
SMT201900619T1 (it) 2020-01-14
US9439850B2 (en) 2016-09-13
JP2020147580A (ja) 2020-09-17
US20190314317A1 (en) 2019-10-17
JP2012525363A (ja) 2012-10-22
CA2760629C (en) 2015-03-24
JP2014005305A (ja) 2014-01-16
ES2745458T3 (es) 2020-03-02
WO2010125340A1 (en) 2010-11-04
DK2424520T3 (da) 2019-09-30
PT2424520T (pt) 2019-10-30
HUE046581T2 (hu) 2020-03-30
JP2022071114A (ja) 2022-05-13
US20150164842A1 (en) 2015-06-18
CN102458391A (zh) 2012-05-16
US10328046B2 (en) 2019-06-25
US8536223B2 (en) 2013-09-17
CN102458391B9 (zh) 2020-09-29

Similar Documents

Publication Publication Date Title
LT2424520T (lt) Pnrr naudojimas odos uždegimo gydymui
IL212793A0 (en) Handpiece for treating skin
IL220074B (en) Apparatus for personal skin treatment
IL224771A (en) Skin Care Device
IL217777A0 (en) Methods for treatment of pain
EP2252318A4 (en) PROCESS FOR TREATMENT OF IGNITION
ZA201208413B (en) Skin treatment composition
IL214664A0 (en) Methods of treating hair related conditions
GB0902040D0 (en) Composition for treatment of skin
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
IL214133A0 (en) Skin treatment
GB0901456D0 (en) Treatment of psoriasis
PL2467128T3 (pl) Zastosowanie triazotanu glicerolu do leczenia obrzęku urazowego
ZA201208568B (en) Skin treatment composition
IL200753A0 (en) Treatment of psoriasis
ZA201108571B (en) Use of pufas to treat nerve damage
GB201012926D0 (en) Compounds for treatment of inflammation
ZA201108493B (en) Method of treating hair
ZA201101821B (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin deases
SI2531124T1 (sl) Naprava za zdravljenje kožnih lezij
GB201010638D0 (en) Composition for treatment of skin
PT2456445E (pt) Agente para o tratamento de condições da pele
ZA201005770B (en) The treatment of damaged skin
PT2461816E (pt) Utilização do xénon para tratar a hipersensibilidade à dor
IL216629A0 (en) Methods of treating inflammation